

Financial Tear Sheet

Corporate Profile

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, including glaucoma. In July 2017, the Company announced top-line results of its Phase 2 fixed-dose combination trial of trabodenoson and latanoprost for the treatment of glaucoma. The trial did not meet its primary efficacy endpoint and the Company has since discontinued development of trabodenoson in order to focus on evaluating strategic alternatives.

Primary IR Contact

US Corporate Headquarters:
Phone: 781-676-2100
E-mail: info@inotekpharma.com

Stock Performance

RCKT (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$16.82
Change (%)	▼ 0.37 (2.15%)
Volume	100,248
52 Week High	\$19.78
52 Week Low	\$3.40
Market Cap	\$648,878,478
Rolling EPS	-5.57
PE Ratio	0
Shares Outstanding	38,577,793

Data as of 02/20/18 4:00 p.m. ET



Recent News & Events

Feb 7, 2018

[Rocket Pharmaceuticals Announces Participation in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Conference](#)

Jan 24, 2018

[Rocket Pharmaceuticals Prices Public Offering of Common Stock](#)

Jan 23, 2018

[Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock](#)

SEC Filings

Filing Date	Form
02/14/18	SC 13G/A
02/14/18	SC 13G/A
02/13/18	SC 13G/A
02/09/18	SC 13G/A

Data provided by Nasdaq. Minimum 15 minutes delayed.

There are currently no events scheduled.

Corporate Governance

David P. Southwell	President and Chief Executive Officer
Rudolf A. Baumgartner, MD	Executive Vice President, Chief Medical Officer
Dale Ritter	Vice President, Finance & Chief Accounting Officer
Claudine Prowse, PhD	Vice President, Strategy, Corporate Development & IRO